In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) - Global Trends & Forecasts to 2016

NEW YORK, May 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) – Global Trends & Forecasts to 2016

http://www.reportlinker.com/p0849772/In-Vitro-Diagnostics-IVD-Market-Clinical-Chemistry-Immunoassays-Molecular-Diagnostics-Hematology-Analyzers--Microbiology-Culture-–-Global-Trends--Forecasts-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) – Global Trends & Forecasts to 2016

The global in-vitro diagnostics (IVD) market was valued at $44 billion in 2011 and is expected to have a modest growth during the study period. The U.S. represented the biggest market for IVD equipments accounting for about a half of the total market. The report studies various segments of the IVD market including Clinical Chemistry, Molecular diagnostics, Immunoassays, Hematology and Microbiology. Clinical chemistry dominates the global IVD market whereas molecular diagnostics is expected to register the highest growth during the study period. Increased patient awareness, patient self testing, rapidly aging population globally and automated testing due to technical advances are the major growth drivers of this market. Key players in the IVD market include Roche Diagnostics, Abbott Diagnostics, Beckman Coulter, BD Diagnostics, and Siemens Diagnostics.

TABLE OF CONTENTS

1.1 KEY TAKE-AWAYS

1.2 REPORT DESCRIPTION

1.3 MARKETS COVERED

1.4 STAKEHOLDERS

1.5 RESEARCH METHODOLOGY

1.5.1 MARKET SIZE

1.5.2 MARKET SHARE

1.5.3 KEY DATA POINTS FROM SECONDARY SOURCE

1.5.4 KEY DATA POINTS FROM PRIMARY SOURCE

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW

3.1 INTRODUCTION

3.2 MARKET SEGMENTATION

3.3 BURNING ISSUE

3.3.1 LAB AUTOMATION FOR INCREASED EFFICIENCY & ACCURATE DIAGNOSIS

3.4 WINNING IMPERATIVE

3.4.1 NON PROPRIETARY SYSTEM WITH ENHANCED FUNCTIONALITIES

3.5 MARKET DYNAMICS

3.5.1 DRIVERS

3.5.1.1 Rising incidence of chronic and infectious diseases in emerging economies to drive the market

3.5.1.2 Rapidly aging population

3.5.1.3 Rise in Point-of-Care testing

3.5.1.4 Personalized medicine to propel growth of the IVD market

3.5.2 RESTRAINTS

3.5.2.1 Lack of budget and labor

3.5.2.2 Stringent regulatory framework to stifle the growth of IVD market

3.6 MARKET SHARE ANALYSIS

3.7 IVD MARKET, BY END-USERS

3.8 IVD MARKET, BY TYPES

4 CLINICAL CHEMISTRY

4.1 OVERVIEW

4.1.1 GENERAL CHEMISTRY

4.1.2 URINE CHEMISTRY ANALYZERS

4.1.3 BLOOD GAS ELECTROLYTE ANALYZERS

4.1.4 URINE CYTOLOGY

4.1.5 CERVICAL CYTOLOGY

5 IMMUNOASSAYS

5.1 OVERVIEW

5.1.1 INFECTIOUS DISEASES

5.1.2 ONCOLOGY

5.1.3 CARDIAC

5.1.4 BLOOD SCREENING

5.1.5 ENDOCRINE

5.1.6 DIABETES

5.1.7 OTHERS

6 MOLECULAR DIAGNOSTICS

6.1 OVERVIEW

6.1.1 INFECTIOUS DISEASES

6.1.2 ONCOLOGY

6.1.3 GENETIC

6.1.4 BLOOD SCREENING

6.1.5 OTHERS

7 HEMATOLOGY

7.1 OVERVIEW

7.1.1 HIGH THROUGHPUT ANALYZER

7.1.2 MEDIUM THROUGHPUT ANALYZER

7.1.3 LOW THROUGHPUT ANALYZER

8 MICROBIOLOGY

8.1 OVERVIEW

8.1.1 BLOOD CULTURE

8.1.2 PATHOLOGICAL CULTURE

8.1.3 IDENTIFICATION & ANTIBIOTIC SUSCEPTIBILITY TESTING

8.1.4 OTHERS

9 OTHERS

9.1 OVERVIEW

10 GEOGRAPHICAL ANALYSIS

10.1 INTRODUCTION

10.2 AMERICAS

10.2.1 U.S.

10.2.2 CANADA

10.2.3 BRAZIL

10.2.4 MEXICO

10.2.5 REST OF AMERICAS

10.3 EUROPE

10.3.1 U.K.

10.3.2 GERMANY

10.3.3 FRANCE

10.3.4 ITALY

10.3.5 SPAIN

10.3.6 RUSSIA

10.3.7 REST OF EUROPE

10.4 ASIA

10.4.1 JAPAN

10.4.2 CHINA

10.4.3 INDIA

10.4.4 REST OF ASIA

10.5 REST OF THE WORLD

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION

11.2 NEW PRODUCTS DEVELOPMENT

11.3 EXPANSIONS

11.4 AGREEMENTS & COLLABORATIONS

11.5 MERGERS & ACQUISITIONS

12 COMPANY PROFILES

12.1 ABBOTT DIAGNOSTICS INC

12.1.1 OVERVIEW

12.1.2 FINANCIALS

12.1.3 PRODUCTS & SERVICES

12.1.4 STRATEGY

12.1.5 DEVELOPMENTS

12.2 ALERE INC

12.2.1 OVERVIEW

12.2.2 FINANCIALS

12.2.3 PRODUCTS & SERVICES

12.2.4 STRATEGY

12.2.5 DEVELOPMENTS

12.3 ARKRAY INC

12.3.1 OVERVIEW

12.3.2 PRODUCTS & SERVICES

12.3.3 STRATEGY

12.3.4 DEVELOPMENTS

12.4 BECKMAN COULTER INC

12.4.1 OVERVIEW

12.4.2 FINANCIALS

12.4.3 PRODUCTS & SERVICES

12.4.4 STRATEGY

12.4.5 DEVELOPMENTS

12.5 BECTON, DICKINSON AND COMPANY

12.5.1 OVERVIEW

12.5.2 FINANCIALS

12.5.3 PRODUCTS & SERVICES

12.5.4 STRATEGY

12.5.5 DEVELOPMENTS

12.6 BIOMERIEUX

12.6.1 OVERVIEW

12.6.2 FINANCIALS

12.6.3 PRODUCTS & SERVICES

12.6.4 STRATEGY

12.6.5 DEVELOPMENTS

12.7 BIO-RAD LABORATORIES INC

12.7.1 OVERVIEW

12.7.2 FINANCIALS

12.7.3 PRODUCTS & SERVICES

12.7.4 STRATEGY

12.7.5 DEVELOPMENTS

12.8 DIASORIN DIAGNOSTIC S.P.A.

12.8.1 OVERVIEW

12.8.2 FINANCIALS

12.8.3 PRODUCTS & SERVICES

12.8.4 STRATEGY

12.8.5 DEVELOPMENTS

12.9 DIAGNOSTICA STAGO SAS

12.9.1 OVERVIEW

12.9.2 FINANCIALS

12.9.3 PRODUCTS & SERVICES

12.9.4 STRATEGY

12.9.5 DEVELOPMENTS

12.10 GEN-PROBE INCORPORATED

12.10.1 OVERVIEW

12.10.2 FINANCIALS

12.10.3 PRODUCTS & SERVICES

12.10.4 STRATEGY

12.10.5 DEVELOPMENTS

12.11 HOLOGIC INC

12.11.1 OVERVIEW

12.11.2 FINANCIALS

12.11.3 PRODUCTS & SERVICES

12.11.4 STRATEGY

12.11.5 DEVELOPMENTS

12.12 HORIBA LTD

12.12.1 OVERVIEW

12.12.2 FINANCIALS

12.12.3 PRODUCTS & SERVICES

12.12.4 STRATEGY

12.12.5 DEVELOPMENTS

12.13 LUMINEX CORPORATION

12.13.1 OVERVIEW

12.13.2 FINANCIALS

12.13.3 PRODUCTS & SERVICES

12.13.4 STRATEGY

12.13.5 DEVELOPMENTS

12.14 MINDRAY MEDICAL INTERNATIONAL LIMITED

12.14.1 OVERVIEW

12.14.2 FINANCIALS

12.14.3 PRODUCTS & SERVICES

12.14.4 STRATEGY

12.14.5 DEVELOPMENTS

12.15 NOVARTIS INTERNATIONAL AG

12.15.1 OVERVIEW

12.15.2 FINANCIALS

12.15.3 PRODUCTS & SERVICES

12.15.4 STRATEGY

12.15.5 DEVELOPMENTS

12.16 ORTHO CLINICAL DIAGNOSTICS (JNJ COMPANY)

12.16.1 OVERVIEW

12.16.2 FINANCIALS

12.16.3 PRODUCTS & SERVICES

12.16.4 STRATEGY

12.16.5 DEVELOPMENTS

12.17 QIAGEN N.V.

12.17.1 OVERVIEW

12.17.2 FINANCIALS

12.17.3 PRODUCTS & SERVICES

12.17.4 STRATEGY

12.17.5 DEVELOPMENTS

12.18 ROCHE DIAGNOSTICS LIMITED

12.18.1 OVERVIEW

12.18.2 FINANCIALS

12.18.3 PRODUCTS & SERVICES

12.18.4 STRATEGY

12.18.5 DEVELOPMENTS

12.19 SIEMENS HEALTHCARE

12.19.1 OVERVIEW

12.19.2 FINANCIALS

12.19.3 PRODUCTS & SERVICES

12.19.4 STRATEGY

12.19.5 DEVELOPMENTS

12.20 SYSMEX CORPORATION

12.20.1 OVERVIEW

12.20.2 FINANCIALS

12.20.3 PRODUCTS & SERVICES

12.20.4 STRATEGY

12.20.5 DEVELOPMENTS

12.21 THERMO FISHER SCIENTIFIC INC

12.21.1 OVERVIEW

12.21.2 FINANCIALS

12.21.3 PRODUCTS & SERVICES

12.21.4 STRATEGY

12.21.5 DEVELOPMENTS

LIST OF TABLES

TABLE 2 GLOBAL CLINICAL CHEMISTRY MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 3 GLOBAL CLINICAL CHEMISTRY MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)

TABLE 4 CLINICAL CONDITIONS & TESTS CONDUCTED

TABLE 5 GLOBAL IMMUNOASSAYS MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 6 GLOBAL IMMUNOASSAYS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)

TABLE 7 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 8 MOLECULAR DIAGNOSTICS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)

TABLE 9 GLOBAL HEMATOLOGY MARKET REVENUE, BY APPLICATIONS, 2009 – 2011 ($BILLION)

TABLE 10 GLOBAL HEMATOLOGY MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)

TABLE 11 GLOBAL MICROBIOLOGY MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 12 GLOBAL MICROBIOLOGY MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)

TABLE 13 GLOBAL OTHERS MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 14 GLOBAL OTHERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)

TABLE 15 IVD MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)

TABLE 16 AMERICAS: IVD MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 17 AMERICAS: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 18 AMERICAS: CLINICAL CHEMISTRY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 19 AMERICAS: IMMUNOASSAYS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 20 AMERICAS: MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 21 AMERICAS: HEMATOLOGY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 22 AMERICAS: MICROBIOLOGY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 23 AMERICAS: OTHERS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 24 AMERICAS: IVD MARKET REVENUE, BY END-USERS, 2009 – 2016 ($BILLION)

TABLE 25 U.S.: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 26 CANADA: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 27 BRAZIL: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 28 MEXICO: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 29 EUROPE: IVD MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 30 EUROPE: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 31 EUROPE: CLINICAL CHEMISTRY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 32 EUROPE: IMMUNOASSAYS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 33 EUROPE: MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($MILLION)

TABLE 34 EUROPE: HEMATOLOGY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 35 EUROPE: MICROBIOLOGY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 36 EUROPE: OTHERS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 37 EUROPE: IVD MARKET REVENUE, BY END-USERS, 2009 – 2016 ($BILLION)

TABLE 38 U.K.: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 39 GERMANY: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 40 FRANCE: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 41 ITALY: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 42 SPAIN: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 43 RUSSIA AGEING POPULATION

TABLE 44 RUSSIA: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 45 ASIA: IVD MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 46 ASIA: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($BILLION)

TABLE 47 ASIA: CLINICAL CHEMISTRY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)

TABLE 48 ASIA: IMMUNOASSAYS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($MILLION)

TABLE 49 ASIA: MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($MILLION)

TABLE 50 ASIA: HEMATOLOGY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($MILLION)

TABLE 51 ASIA: MICROBIOLOGY MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($MILLION)

TABLE 52 ASIA: OTHERS MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($MILLION)

TABLE 53 ASIA: IVD MARKET REVENUE, BY END-USERS, 2009 – 2016 ($BILLION)

TABLE 54 JAPAN: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($MILLION)

TABLE 55 CHINA: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($MILLION)

TABLE 56 INDIA: IVD MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($MILLION)

TABLE 57 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 58 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 59 ABBOTT LABORATORIES: TOTAL REVENUE, GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 60 ALERE INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 61 ALERE INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 62 ALERE INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 63 BECKMAN COULTER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 64 BECKMAN COULTER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 65 BECKMAN COULTER INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 66 BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 67 BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 68 BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 69 BIOMERIEUX S.A.: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 70 BIOMERIEUX S.A.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 71 BIOMERIEUX S.A.: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 72 BIO-RAD LABORATORIES INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 73 BIO-RAD LABORATORIES INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 74 BIO-RAD LABORATORIES INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 75 DIASORIN DIAGNOSTIC S.P.A.: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 76 DIASORIN DIAGNOSTIC S.P.A.: TOTAL REVENUE, BY TECHNOLOGY, 2008 – 2010 ($MILLION)

TABLE 77 DIASORIN DIAGNOSTIC S.P.A: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 78 GEN-PROBE INCORPORATED: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 79 GEN-PROBE INCORPORATED: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 80 GEN-PROBE INCORPORATED: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 81 HOLOGIC INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 82 HOLOGIC INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 83 HORIBA LTD: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 84 HORIBA LTD: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 85 LUMINEX CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 86 LUMINEX CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 87 LUMINEX CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 88 MINDRAY MEDICAL INTERNATIONAL LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)

TABLE 89 MINDRAY MEDICAL INTERNATIONAL LIMITED: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 90 MINDRAY MEDICAL INTERNATIONAL LIMITED: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 91 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2011 ($MILLION)

TABLE 92 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS, 2008 – 2011 ($MILLION)

TABLE 93 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 94 ORTHO CLINICAL DIAGNOSTICS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 95 ORTHO CLINICAL DIAGNOSTICS: TOTAL REVENUE, BY MEDICAL DEVICES SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 96 JOHNSON & JOHNSON: TOTAL REVENUE, BY DIAGNOSTICS SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 97 JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 98 QIAGEN N.V: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 99 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 100 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 101 ROCHE: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 102 ROCHE: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 103 SIEMENS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 104 SIEMENS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 105 SIEMENS: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

TABLE 106 SYSMEX CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)

TABLE 107 SYSMEX CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)

TABLE 108 SYSMEX CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)

TABLE 109 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)

TABLE 110 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

TABLE 111 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)

LIST OF FIGURES

FIGURE 2 GLOBAL IVD MARKET SHARE, BY COMPANY, 2011

FIGURE 3 GLOBAL IVD MARKET SHARE, BY END-USERS, 2011

FIGURE 4 GLOBAL IVD MARKET SHARE, BY TYPES, 2011

FIGURE 5 CHANGES IN LONG TERM CARE EXPENDITURE OF JAPAN, 2006 – 2055 ($BILLION)

FIGURE 6 KEY GROWTH STRATEGIES, 2009 – 2011

To order this report:In Vitro Diagnostic Industry: In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) – Global Trends & Forecasts to 2016

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

21%

more press release views with 

Request a Demo